TELO Telomir Pharmaceuticals Inc

$TELO why is RF Kennedy one of 12 people following TELO on his personal account on twitter?????? Pure speculation but -As the Secretary of Health and Human Services (HHS), Robert F. Kennedy Jr. does not directly approve or fast-track individual drugs himself, but he exercises supervisory authority to direct the Food and Drug Administration (FDA) to prioritize, streamline, or create expedited review pathways for specific categories of treatments

$TELO they are trying to cover but there are two problems - no volume and the trial is about to start

$TELO On September 14, 2026, Telomir Pharmaceuticals, Inc. (the “Company”) issued a press release announcing new research findings from The Ohio State University College of Veterinary Medicine demonstrating that Telomir-Zn produces inhibition of cell growth across human and canine osteosarcoma models. The study examined Telomir-Zn across three osteosarcoma cell line models: HOS (human), D17 (canine), and Abrams (canine). Researchers evaluated the dose-dependent anti-tumor activity of Telomir-Zn across all three models, with all three osteosarcoma cell lines demonstrating growth inhibition at similar low drug concentrations. The findings support further translational investigation. Making moves!!!

$TELO sitting in the teens for what seemed like forever and now back in the 20s on zero news makes me think someone bought in bigly

$TELO This is not a phase 1 trial-Study Overview Brief Summary This is a first-in-human, multicenter, open-label Phase I/II study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of oral Zn-Telomir monotherapy in adults with advanced or metastatic triple-negative breast cancer. Phase I uses a modified 3+3 dose-escalation design to determine safety, tolerability, maximum tolerated dose, and recommended Phase II dose. Phase II uses a Simon two-stage expansion design at the recommended Phase II dose to evaluate preliminary antitumor activity, including objective response rate per Response Evaluation Criteria in Solid Tumors. Official Title A First-in-Human (FIH), Phase I/II, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Antitumor Activity of Zn-Telomir Administered Orally as Monotherapy in Patients With Advanced or Triple-Negative Breast Cancer

$TELO It is going to need more than a $ 5.6 million influx; it needs more analysts saying it's a buy...

$TELO I Bought a little more Telo here, this is a stock that will really moon as soon as they figure it all out. $5. will easily come in time

$TELO youre thinking about this wrong. the price will stay low unless something massive happens like pfizer offering to buy. this stock is a lottery ticket just like all clinical pharma companies.

$TELO This is actually huge news imo. People on that teir of society know full well what a follow from them means.